comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 00:35:03 - browse：53982

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

WSS

Apple Vision Pro: A first look at health apps on the new VR headset

Cybersecurity threat forces Lurie Children's to take systems offline

A $475,000 price tag for a new cancer drug: crazy or meh?

Woodcock on FDA’s accelerated approval and her next chapter

Apple Vision Pro: A first look at health apps on the new VR headset

ARCH Venture Partners is raising $3 billion for a life sciences fund

knowledge

comprehensive

leisure time

Medical records are filled with copy

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Drug repurposing or repositioning? The language matters

Cybersecurity threat forces Lurie Children's to take systems offline

After affirmative action ruling, medical educators look to 'holistic review'

Do digital therapeutics have a future in medicine?

Peter Hotez and the public health issue of online harassment

Cognito secures funding to test medical device for Alzheimer's

focus

Some dementia cases could be undiagnosed liver disease

What we need to know about Arena Bioworks

Commercial surrogacy can be ethical, despite pope’s claims

Time to name cancers by genetics, not organ of origin, expert says

Quicker fix for pulse oximeters urged during FDA public meeting

FDA drug safety: Singulair case shows systemic surveillance flaws

focus

focus

leisure time

focus